Zobrazeno 1 - 10
of 167
pro vyhledávání: '"Christopher A Eide"'
Autor:
C James Chou, Thomas O'Hare, Sophie Lefebvre, David Alvarez, Jeffrey W Tyner, Christopher A Eide, Brian J Druker, Joel M Gottesfeld
Publikováno v:
PLoS ONE, Vol 3, Iss 10, p e3593 (2008)
Chronic myeloid leukemia (CML) is characterized by the presence of a constitutively active Abl kinase, which is the product of a chimeric BCR-ABL gene, caused by the genetic translocation known as the Philadelphia chromosome. Imatinib, a selective in
Externí odkaz:
https://doaj.org/article/d83406817199459d9571c73c82d75f88
Autor:
Mayra A. Gonzalez, Idaly M. Olivas, Alfonso E. Bencomo‐Alvarez, Andres J. Rubio, Christian Barreto‐Vargas, Jose L. Lopez, Sara K. Dang, Jonathan P. Solecki, Emily McCall, Gonzalo Astudillo, Vanessa V. Velazquez, Katherine Schenkel, Kelaiah Reffell, Mariah Perkins, Nhu Nguyen, Jehu N. Apaflo, Efren Alvidrez, James E. Young, Joshua J. Lara, Dongqing Yan, Anna Senina, Jonathan Ahmann, Katherine E. Varley, Clinton C. Mason, Christopher A. Eide, Brian J. Druker, Md Nurunnabi, Osvaldo Padilla, Sudip Bajpeyi, Anna M. Eiring
Publikováno v:
Clinical and Translational Medicine, Vol 12, Iss 12, Pp n/a-n/a (2022)
Abstract Tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 have turned chronic myeloid leukaemia (CML) from a fatal disease into a manageable condition for most patients. Despite improved survival, targeting drug‐resistant leukaemia stem cells
Externí odkaz:
https://doaj.org/article/0d778c96fbce4f62a37c6a5e642b07ee
Autor:
Jessica Leonard, Joelle SJ Wolf, Michelle Degnin, Christopher A. Eide, Dorian LaTocha, Kyle Lenz, Beth Wilmot, Charles G. Mullighan, Mignon Loh, Stephen P Hunger, Brian J Druker, Marc M Loriaux, Jeffrey W Tyner, Bill H Chang
Publikováno v:
Haematologica, Vol 106, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/2901a1309bc34ddbb96064c714b750fc
Autor:
Alisa Damnernsawad, Daniel Bottomly, Stephen E. Kurtz, Christopher A. Eide, Shannon K. McWeeney, Jeffrey W. Tyner, Tamilla Nechiporuk
Publikováno v:
Haematologica, Vol 107, Iss 1 (2020)
Drug resistance impedes the long-term effect of targeted therapies in acute myeloid leukemia (AML), necessitating the identification of mechanisms underlying resistance. Approximately 25% of AML patients carry FLT3 mutations and develop post-treatmen
Externí odkaz:
https://doaj.org/article/77ae0d83a6244d158ead1609052ab16a
Autor:
Haijiao Zhang, Samantha Savage, Anna Reister Schultz, Daniel Bottomly, Libbey White, Erik Segerdell, Beth Wilmot, Shannon K. McWeeney, Christopher A. Eide, Tamilla Nechiporuk, Amy Carlos, Rachel Henson, Chenwei Lin, Robert Searles, Hoang Ho, Yee Ling Lam, Richard Sweat, Courtney Follit, Vinay Jain, Evan Lind, Gautam Borthakur, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Jorge Cortes, Robert Collins, Daelynn R. Buelow, Sharyn D. Baker, Brian J. Druker, Jeffrey W. Tyner
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance o
Externí odkaz:
https://doaj.org/article/998f439604e74cef95464ecda676fa5a
Autor:
Alyssa Carey, David K. Edwards, V, Christopher A. Eide, Laura Newell, Elie Traer, Bruno C. Medeiros, Daniel A. Pollyea, Michael W. Deininger, Robert H. Collins, Jeffrey W. Tyner, Brian J. Druker, Grover C. Bagby, Shannon K. McWeeney, Anupriya Agarwal
Publikováno v:
Cell Reports, Vol 18, Iss 13, Pp 3204-3218 (2017)
Secreted proteins in the bone marrow microenvironment play critical roles in acute myeloid leukemia (AML). Through an ex vivo functional screen of 94 cytokines, we identified that the pro-inflammatory cytokine interleukin-1 (IL-1) elicited profound e
Externí odkaz:
https://doaj.org/article/381cf8ee8bde4d07ae49773000f6b9fe
Autor:
Evan J. Barnes, Christopher A. Eide, Andy Kaempf, Daniel Bottomly, Kyle A. Romine, Beth Wilmot, Dominick Saunders, Shannon K. McWeeney, Cristina E. Tognon, Brian J. Druker
Publikováno v:
British Journal of Haematology. 200:323-328
Drug resistance in chronic myeloid leukaemia (CML) may occur via mutations in the causative BCR::ABL1 fusion or BCR::ABL1-independent mechanisms. We analysed 48 patients with BCR::ABL1-independent resistance for the presence of secondary fusion genes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fe24e8b56fb4ff27940aa7049f0526a
https://doi.org/10.1111/bjh.18515
https://doi.org/10.1111/bjh.18515
Autor:
Olivia M. Lucero, Ji-Ann Lee, Jenna Bowman, Kara Johnson, Gopal Sapparapu, John K. Thomas, Guang Fan, Bill H. Chang, Karina Thiel-Klare, Christopher A. Eide, Craig Okada, Mike Palazzolo, Evan Lind, Yoko Kosaka, Brian J. Druker, Nicholas Lydon, Peter M. Bowers
Publikováno v:
Clinical Cancer Research.
Purpose: Targeted therapeutics are a goal of medicine. Methods for targeting T-cell lymphoma lack specificity for the malignant cell, leading to elimination of healthy cells. The T-cell receptor (TCR) is designed for antigen recognition. T-cell malig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0406b605cf292eed569ab610404cdc6a
https://doi.org/10.1158/1078-0432.ccr-22-0906
https://doi.org/10.1158/1078-0432.ccr-22-0906
Autor:
Christopher A. Eide, Stephen E. Kurtz, Andy Kaempf, Nicola Long, Sunil K Joshi, Tamilla Nechiporuk, Ariane Huang, Charles Dibb, Daniel Bottomly, Shannon K. McWeeney, Bill H. Chang, Brian J. Druker, Jeffrey W. Tyner
Publikováno v:
Blood. 140:1025-1027
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e751f5e61f669bd3ee09692c4a7d6cbe
https://doi.org/10.1182/blood-2022-159264
https://doi.org/10.1182/blood-2022-159264
Autor:
Stephen E. Kurtz, Christopher A. Eide, Andy Kaempf, Nicola Long, Daniel Bottomly, Olga Nikolova, Brian J. Druker, Shannon K. McWeeney, Bill H. Chang, Jeffrey W. Tyner, Anupriya Agarwal
Publikováno v:
Blood Advances. 6:3062-3067
Using ex vivo drug screening of primary patient specimens, we identified the combination of the p38 MAPK inhibitor doramapimod (DORA) with the BCL2 inhibitor venetoclax (VEN) as demonstrating broad, enhanced efficacy compared with each single agent a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce5c5b23cccbc67a93f4c286567a32c5
https://doi.org/10.1182/bloodadvances.2021006307
https://doi.org/10.1182/bloodadvances.2021006307